ACCESS Newswire

Digostics Limited

Share
Digostics and AgaMatrix Partner to Introduce Oral Glucose Tolerance Home Testing for UK Expectant Mothers

Digostics and AgaMatrix Team Up to Improve Gestational Diabetes Screening for UK Women via the Introduction of Oral Glucose Tolerance Home Testing

OXFORD, UK / ACCESSWIRE / April 10, 2024 / Digital clinical diagnostics and diabetes home testing provider Digostics Limited announced today a new commercial partnership with leading diabetes technology company, AgaMatrix Europe Limited, designed to accelerate the introduction of Digostics' home oral glucose tolerance testing (OGTT) service, GTT@home, for gestational diabetes (GDM) screening within the UK National Health Service (NHS).

GTT@home represents the world's first and only commercially available OGTT approved for home use. The partnership enables AgaMatrix to distribute GTT@home to the NHS on an exclusive basis. This news also follows the recent announcement of the significantly improved uptake in OGTT attributed to home testing experienced by University Hospital Southampton (UHS), and GTT@home's full inclusion in the Laboratory Diagnostics, Point of Care Testing and Pathology Managed Services framework operated by NHS Supply Chain.

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

Image: The GTT@home Test Kit includes the novel test device, a preformulated glucose drink, finger prickers, a test user guide and a prepaid envelope. It is packaged to fit safely in the recipient's home letterbox.

"The significant reductions in maternity services workload and improvements in test accessibility achieved by taking GDM screening directly to the expectant mother has generated huge domestic and international demand for GTT@home," said James Jackson, CEO and Founder of Digostics. "AgaMatrix is the perfect partner to help Digostics expedite GTT@home's UK introduction based on its existing relationships and customer base within NHS maternity services and their unparalleled domain expertise in GDM monitoring."

While the OGTT is the gold standard in GDM screening, delayed and missed tests are common based on the inconvenience for women and complexity for healthcare providers of the traditional clinic-based method of OGTT delivery. OGTT uptake is also unfortunately lowest with those patient groups most at-risk of developing the condition.

GTT@home removes the barriers associated with effective diabetes screening by enabling women to test for glucose intolerance outside of the clinic for the very first time. Home testing offers the same level of accuracy as clinic tests but without any of the staffing requirements, risks of sample degradation and laboratory delays that often impact clinic testing capacity, contribute to screening backlogs and cause false negative tests.

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

Image: With GTT@home, the user can send their test data directly to their antenatal care team with a simple scan of a snap-off fob attached to the test device using the NFC functionality within their smartphone.

"Our daily interaction with customers means we see up close just how difficult it is for maternity service departments to deliver timely GDM testing. We also know just how excited they are at the prospect of being able to improve their testing throughput by introducing home screening," said Alec Winton, Business Manager Europe, AgaMatrix Europe. "We could not be more excited to partner with Digostics and to add GTT@home to our growing portfolio of ways in which we can assist the NHS manage diabetes in pregnancy."

With GTT@home simplifying GDM testing and AgaMatrix' technologies assisting with the management of those diagnosed positive, the partnership also provides additional scope for a closer technical integration between their respective solutions.

"The complementary nature of Digostics' and AgaMatrix' services bridges a technical gap between GDM testing and post-diagnosis care," said Arif Govani, Chief Digital and Data Officer, Digostics. "However, we are not stopping there in our efforts to make things easier for diabetes midwifery professionals. We are already exploring ways in which we can make the testing and diabetes patient onboarding process even more seamless through full-service integration."

NHS Supply Chain's Laboratory Diagnostics, Point of Care Testing and Pathology Managed Services framework started on the 12th March 2024 and runs for four years. GTT@home's inclusion on this framework makes it easier for NHS hospitals looking to reduce their testing backlogs by drawing on the Digostics service. GTT@home is also regulatory approved for use within the European Union. Additionally, Digostics is currently launching international operations in the Middle East and Asia Pacific to meet the significant demand for oral glucose tolerance home testing in these regions.

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
Image: GTT@home enables the expectant mother to complete her OGTT from home and without needing to attend clinic.

***

About Digostics

Far too many people across the world are living with undiagnosed diabetes.

UK-based Digostics' mission is to enable healthcare providers to identify everyone with diabetes, and those at risk of developing diabetes, by eliminating the common barriers that inhibit accurate and timely testing using the gold standard oral glucose tolerance test (OGTT).

Digostics is proud to offer GTT@home - the world's first home OGTT offering and the most accessible and scalable way for clinical teams to realise their diabetes testing objectives.

To learn more, visit www.digostics.com

About AgaMatrix Europe Ltd

AgaMatrix Europe Ltd is a wholly owned subsidiary of AgaMatrix Inc. based in New Hampshire, USA. AgaMatrix Inc. was acquired by global in-vitro diagnostics company, i-SENS, in July 2023.

AgaMatrix designs, develops, manufactures, and supplies innovative diagnostic and data management technologies for diabetes care.

AgaMatrix Europe is a leading supplier of blood glucose monitoring and support services to Gestational Diabetes Clinics nationwide. The WaveSense JAZZ™ blood glucose test strip is the second most prescribed in the UK. It is used in the WaveSense JAZZ™ WIRELESS meter, which syncs automatically to the AgaMatrix Diabetes Manager app, and is a popular choice for HCPs to monitor Gestational Diabetes.

AgaMatrix has sold over 8 million blood glucose monitors and over 3 billion test strips since the Company's 2001 inception.

Media Contact(s)

Graeme Collins, Digostics
Mobile: +44 (0)7854 664168
Email: gc@digostics.com

SOURCE: Digostics Limited



View the original press release on accesswire.com

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

Karbon-X Becomes Official Name Sponsor of BK Dukes Basketball Team8.7.2025 09:00:00 CEST | Press release

CALGARY, AB / ACCESS Newswire / July 8, 2025 / Karbon-X Corp. (OTCQX:KARX), a vertically integrated climate solutions company, has signed a multi-year agreement to become the official name sponsor of BK Dukes, one of Austria's top professional basketball teams. Effective immediately, the team will compete as the BK Karbon-X Dukes. This partnership brings together two high-performance organizations committed to community, innovation, and progress chon and off the court. Fresh off their 2024-2025 Austrian Cup Title win, the BK Dukes are working with Karbon-X to integrate measurable sustainability initiatives throughout the organization. This includes annual emissions reporting, offsetting all team and venue Scope 1, 2, and 3 emissions, and incorporating an emissions offset fee into every ticket purchase to address fan-related impacts. Together, they are building a model of leadership that extends far beyond the scoreboard. "This partnership represents what climate action should look like

Polaris Renewable Energy Announces Q1 2025 Investor Call Details7.7.2025 22:10:00 CEST | Press release

TORONTO, ON / ACCESS Newswire / July 7, 2025 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company") is pleased to announce it will be holding its Earnings Conference Call and Webcast to report its Q2 2025 Earnings Results on Thursday, July 31st, 2025, at 10:00 am EST. To listen to the call, please dial Toll Free 888-506-0062 or International Toll-Free Number 973-528-0011 entry code 108489. or URL: https://www.webcaster4.com/Webcast/Page/2773/51833 A digital recording of the earnings call will be available for replay two hours after the call's completion. Replay Call Information: Toronto: 1 877-481-4010, Passcode: 51833 International (toll-free): 1 919-882-2331, Passcode: 51833 Encore Replay Expiration Date: August 14, 2025 About Polaris Renewable Energy Inc. Polaris Renewable Energy Inc. is a Canadian publicly traded company engaged in the acquisition, development, and operation of renewable energy projects in Latin America and the Caribbean. We are a high-performing an

Innodata to Report Second Quarter 2025 Results7.7.2025 14:30:00 CEST | Press release

NEW YORK, NY / ACCESS Newswire / July 7, 2025 / INNODATA INC. (Nasdaq:INOD) today announced that it will report Second Quarter 2025 results after the market closes on Thursday, July 31, 2025. A news release will be available in both the News and Investor Relations sections of the Innodata website, www.innodata.com Innodata has scheduled an investor conference call for 5:00 PM Eastern time on that same day. The call-in numbers for the conference call are: (+1) 800 549 8228 North America (+1) 289 819 1520 International Participant Access Code 18067# Investors are also invited to access a live Webcast of the conference call at the Investor Relations section of Innodata's website at https://investor.innodata.com/events-and-presentations/. Please note that the Webcast feature will be in listen-only mode. Call-in replay will be available for seven days following the conference call, and Webcast replay will be available for 30 days following the conference call, at the Investor Relations sect

GoodData Launches AI for Self-Hosted Analytics: Powerful, Proven, Private7.7.2025 14:30:00 CEST | Press release

GoodData AI capabilities, including AI Assistant and Smart Search, now available for self-hosted deployment. Keep your data private, compliant, and AI-fuelled. SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / July 7, 2025 / GoodData, the AI-native analytics platform, today announced GoodData AI is now available for self-hosted deployment. Enterprises can now run GoodData AI, including AI Assistant and Smart Search, entirely within their own infrastructure - on-premises or in a private cloud - with zero third-party data exposure. With this launch, GoodData delivers the full promise of AI-driven analytics while honoring the strict privacy, compliance, and control requirements of modern enterprises. Self-hosting gives organizations total ownership of their analytics workflows, from natural language queries to insight generation, all within their secure perimeter. "Enterprises shouldn't have to choose between innovation and control. With self-hosted GoodData AI, we're giving our customers the

Fineqia's Yield-Bearing Bitcoin ETP Garners $13.9 Mln; Total Co. AUM Reaches $36 Mln7.7.2025 11:30:00 CEST | Press release

LONDON, UK / ACCESS Newswire / July 7, 2025 / Fineqia International Inc. ("Fineqia") (CSE:FNQ)(Frankfurt:FNQA), a digital asset and investment business, announces that its recently launched yield-bearing Bitcoin (BTC) Exchange-Traded Product (ETP), Fineqia Bitcoin Yield ETP (Ticker:YBTC, ISIN:LI1444931821), has surpassed $13.9 million in assets under management (AUM). The sum reflects strong demand for yield-enhanced digital asset products, particularly BTC ones, among Europe's institutional and professional investors. The product issued by Fineqia AG, the company's Liechtenstein-based subsidiary, takes its total AUM to $36 million represented by YBTC's $13.9 million and $22.1 million via its Fineqia FTSE Cardano Enhanced Yield ETN (Ticker:YADA; ISIN:LI1408648106), listed earlier this year. YADA is listed on both the Vienna and Stuttgart stock exchanges. The Fineqia BTC Yield ETP, listed on the Wiener Börse, is the first of its kind to combine Bitcoin exposure with yield-generating act

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye